MEPSGEN

MEPSGEN

생명공학 연구

Songpa-gu Seoul 팔로워 622명

Micro Engineered Physiological Systems Guiding and Enabling the Next

소개

MEPSGEN, a biotech founded by YongTae Kim and Robert Langer in 2019, develops microengineered physiological systems so called organ-on-a-chip and uses the manufactured systems to study pathophysiological mechanisms of key diseases and screen new drug candidates for the treatment. With these studies supported by the technologies, the company has its own multiple new drug candidates, representative ones of which target Alzheimer's and brain tumors. The company specializes in developing and producing a 3D cell culture Microphysiological System platform and in discovering new therapeutics using nanomedicine technology. The products and services include improved accuracy in evaluating new drug candidates and reducing cost and duration of the development. The company carries out fundamental biological research and drug candidate test in an environment equipped with an organ-level function of connected human tissues, rather than studying in a traditional in-vitro experimental model using 2D cell culture, thereby enabling researchers to further verify the findings in more pathophysiologically relevant environments. MEPSGEN is holding many patents, patents pending, and numerous IP licenses in the biotechnology field. For more information visit www.mepsgen.com [ Industry ] Drug Discovery Drug Delivery Biotechnology [ Technology ] MEPS-X series - 3D Microphysiological System platforms MST-X series - Microvortex System, Nanoparticle manufacturing platform MG-X series – Nanomedicine, Biomimetic nanomaterial-based targeted drug delivery platforms

웹사이트
http://www.mepsgen.com
업계
생명공학 연구
회사 규모
직원 11-50명
본사
Songpa-gu Seoul
유형
비상장기업
설립
2019

위치

MEPSGEN 직원

업데이트

비슷한 페이지

자금조달

MEPSGEN 총 1라운드

마지막 라운드

시리즈 A

US$3,375,955.00

크런치베이스에서 자세히 알아보기